RESEARCH ARTICLE

Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer: A meta-analysis

Junhua Yu¹, Huiling Liu², Xueyun Zeng¹, Yujun Zhao¹, Dejun Jiang¹, Hang Lu¹, Jun Qian¹*¹

¹ Department of General Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, People’s Hospital of Quzhou, Quzhou, Zhejiang, China, ² Department of Pharmacy, Zhejiang Quhua Hospital, Quzhou, Zhejiang, China

* iqk976@163.com

Abstract

Background
In recent years, many studies have explored the potential prognostic utility of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer (GC), however, the results remain conflicting. We thus performed a meta-analysis to determine the association of CAR and prognosis of GC.

Methods
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. PubMed, Web of science, Embase, and Cochrane Library were searched. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and cancer-specific survival (CSS) of included studies were pooled to estimate the prognostic value of CAR.

Results
Eight studies with a total of 3,216 patients were included in this meta-analysis. High CAR was significantly associated with poor OS (HR = 1.59, 95% CI = 1.36–1.85, p < 0.001) and worse CSS (HR = 1.65, 95% CI = 1.21–2.25, p = 0.002). In addition, high CAR was significantly associated with male sex (OR = 1.80, 95% CI = 1.31–2.47, p < 0.001), advanced tumor stage (OR = 2.14, 95% CI = 1.48–3.09, p < 0.001), and tumor size ≥ 3 cm (OR = 2.69, 95% CI = 1.84–3.93, p < 0.001).

Conclusion
Elevated pretreatment CAR is a prognostic marker of poor OS and CSS in patients with GC. Furthermore, high CAR levels are associated with clinicopathological features reflecting tumor progression.
**Introduction**

Gastric cancer (GC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related death around the world [1]. GC is a global health burden and it is estimated that 1,033,701 new GC cases and 782,685 deaths occurred in 2018 worldwide [2]. The risk factors of GC include *H. pylori* infection, geographical location, socioeconomic status, and age [3]. Surgery is the only chance for curative treatment; and implementation of a multidisciplinary approach is mandatory and improves survival outcomes [4]. The prognosis of GC depends largely on the stage at initial diagnosis. The 5-year overall survival (OS) rate for patients with GC is 65% without metastases [3], whereas advanced disease carries a dismal prognosis with the median survival of 4–12 months and a 5-year OS rate <5% [4, 5]. Recent progress of treatment of GC improved the survival outcomes of patients. Immune checkpoint inhibitors (ICI) including nivolumab and pembrolizumab has been emerging as a novel treatment strategy for advanced GC [6]. Recent research points to CAR-T immunotherapy as a promising treatment for GC [7]. Prognostic markers including platelet count, CA 19–9, CEA, and neutrophil-to-lymphocyte ratio (NLR) are reported to be highly associated with prognosis of GC [8]. Because of poor prognosis of patients with late-stage, it is important to identify simple and useful biomarkers to help prognostic assessment and therapeutic modalities selection.

Growing evidence has proven that inflammatory responses and nutritional status exert pivotal roles in carcinogenesis, progression, and metastasis of cancer [9–11]. C-reactive protein (CRP) is an acute phase marker of inflammation and is reported to associate with inferior prognosis in various cancers [12]. CRP is produced by hepatocytes, mainly in response to interleukin 6 (IL-6) secreted by T cells and macrophages, which regulates the production of CRP at the transcriptional level [13]. CRP is a sensitive marker of systemic inflammation [14]. Moreover, patients with cancer experience physical and metabolic effects of the disease, and inadequate food intake caused by anticancer treatment, often leads to the malnutrition state of patients [15]. Serum albumin (ALB) is an indicator of nutritional status and hypoalbuminemia suggests that the overall condition of patients is poor [16]. Recent studies report that the C-reactive protein/albumin ratio (CAR), as a novel inflammation biomarker, has shown independent prognostic effect in various types of cancer, including hepatocellular carcinoma [17], renal cell carcinoma [18], esophageal cancer [19], and colorectal cancer [20]. A recent study showed that CAR was an independent predictor for postoperative complications following gastrectomy of GC [21]. Another study indicated that CAR was strongly associated with poor prognosis in patients who underwent surgery for esophagogastric junction and upper gastric cancer (UGC). Many studies also investigated the association of CAR and prognosis in GC, with the results remain controversial [22–29]. Therefore, we aggregated data of eligible studies and performed a meta-analysis to quantify the prognostic role of CAR in GC.

**Materials and methods**

**Literature strategy**

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [30]. The electronic databases of PubMed, Web of science, Embase, and Cochrane Library were comprehensively searched through 10 November 2019. The combinations of following text words and Medical Subjects Heading [MeSH] terms were used for search: (“C-reactive protein to albumin ratio” OR “C-reactive protein/albumin ratio” OR “CRP/Alb ratio” OR “C-reactive protein Albumin ratio”) AND (“gastric cancer” OR “gastric carcinoma” OR “stomach cancer” OR “stomach neoplasm”). The references list of included articles and recent reviews were also manually searched for potential
eligible studies. Ethical approval was not required for this meta-analysis since all used data were extracted from previous publications and no personal data were involved.

Eligible criteria
The eligible studies must meet the following inclusion criteria: (1) GC was pathologically diagnosed; (2) pretreatment CAR was evaluated by serum-based methods; (3) the association between CAR and prognosis of patients including OS and/or cancer-specific survival (CSS) was estimated or sufficient data to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) were provided; (4) a cut-off value of CAR was identified; (5) full-text published in English language. Exclusion criteria were as follows: (1) conference abstracts, reviews, letters, or case reports; (2) studies with insufficient data for analysis; (3) non-human studies; (4) duplicate studies.

Data extraction and quality assessment
All studies were reviewed by two investigators (J.Y. and H.L.) independently, and all discrepancies were resolved by discussion. The extracted information included the following items: first author, year of publication, country, sample size, enrollment time, patient age, sex, tumor node metastasis (TNM) stage, study type, follow-up time, cut-off value, treatment, survival outcomes and HRs and 95%CIs. When univariate and multivariate analyses were both conducted, the data of multivariate analysis were extracted from included studies. The quality of included studies was evaluated according to Newcastle-Ottawa Scale (NOS) [31]. The NOS evaluates the quality of 3 perspectives: selection, comparability, and clinical outcomes, with a score ranging from 0 to 9. A study with a NOS score ≥6 is regarded as of high quality.

Statistical analysis
The Stata SE 12.0 (Stata Corporation, College Station, TX, USA) was used to perform all calculations in this meta-analysis. HRs and 95%CIs for OS and CSS of included studies were pooled to estimate the prognostic value of CAR. The heterogeneity of all studies was assessed by using Cochran’s Q test and Higgins $I^2$ test. When significant heterogeneity was observed ($I^2 > 50\%$ and/or $P < 0.10$), a random-effects model was used; otherwise, a fixed-effects model was adopted. The correlation of CAR and clinicopathological features was evaluated by pooling odds ratios (ORs) and 95%CIs. Subgroup analyses stratified by country, treatment, cut-off value, and TNM stage were performed. These confounders were extracted from each individual study included in this meta-analysis. Publication bias was evaluated using Begg’s test. A $p < 0.05$ was identified as statistically significant.

Results
Study selection process
The flowchart of study selection process is presented in Fig 1. Initial literature search identified 123 records; and after duplicates were removed, 92 records were screened. Based on titles and abstracts evaluation, 73 studies were excluded and 19 studies were further evaluated by full-text examination. Eleven full-text articles were excluded by the following reasons: 9 studies lacked sufficient data, 1 study was a duplicate study, and 1 study did not focus on GC. Finally, 8 studies with a total of 3,216 patients [22–29] were included in this meta-analysis.

Characteristics of included studies
The baseline characteristics of these 8 included studies were summarized in Table 1. All studies were conducted in Asia in two countries; 5 in China [22, 23, 25, 28, 29] and 3 in Japan [24, 26,
The sample sizes ranged from 240 to 688; and the median value was 392.5. Six studies with 2,127 patients [22–27] reported the association between CAR and OS and 3 studies with 1473 patients [24, 28, 29] provided the data of CAR on CSS. Seven studies were of retrospective study design [22–28] and 1 study was a prospective study [29]. The cut-off values of CAR ranged from 0.0232 to 0.5897 in included studies. The NOS scores of included studies ranged from 6 to 9, with a median value of 7.5, indicating that all included studies were of high-quality.
Correlation between pretreatment CAR and OS

A total of 6 studies involving 2,127 patients [22–27] explored the relationship of CAR and OS in GC. As shown in Fig 2 and Table 2, the combined results indicated that high CAR was significantly associated with poor OS (HR = 1.59, 95%CI = 1.36–1.85, p < 0.001), with no significant heterogeneity ($I^2 = 0, P = 0.628$). The subgroup analysis was carried out based on 3 variables: country, treatment, cut-off value, and TNM stage. As summarized in Table 2, the pooled data demonstrated that elevated CAR remained a significant marker of inferior OS irrespective of country, treatment, cut-off value, or TNM stage.

Association of pretreatment CAR and CSS

Three studies enrolling 1473 patients [24, 28, 29] were examined for the prognostic role of CAR on CSS. Because of on significant heterogeneity ($I^2 = 0, P = 0.628$), the subgroup analysis was carried out based on 3 variables: country, treatment, cut-off value, and TNM stage. As summarized in Table 2, the pooled data demonstrated that elevated CAR remained a significant marker of inferior OS irrespective of country, treatment, cut-off value, or TNM stage.

Relationship between CAR and clinicopathological features

To further investigate the prognostic value of CAR in clinical practice, the association between CAR and 6 clinicopathological factors were analyzed. A total of 3 studies consisting 850 patients [22, 23, 25] provided the data. As shown in Fig 4A–4F and Table 3, forest plots showed that high CAR was significantly associated with male sex (OR = 1.80, 95%CI = 1.31–2.47, p < 0.001), advanced tumor stage (OR = 2.14, 95%CI = 1.48–3.09, p < 0.001), and tumor size $\geq$3cm (OR = 2.69, 95%CI = 1.84–3.93, p < 0.001). However, there was no significant correlation between CAR and age (OR = 1.44, 95%CI = 0.89–2.33, p = 0.141), tumor location (OR = 0.86, 95%CI = 0.40–1.81, p = 0.682), or platelets counts (OR = 2.40, 95%CI = 0.67–8.56, p = 0.179) (Fig 4 and Table 3).

Publication bias

Potential publication bias was evaluated by using Begg’s funnel plot. As shown in Fig 5A and 5b, the funnel plot was symmetric and no significant publication bias was detected (p = 0.133 for OS and p = 1 for CSS).

M, male; F, female; NR, not reported; OS, overall survival; CSS, cancer-specific survival; MV, multivariate; UV, univariate; NOS, Newcastle-Ottawa Scale; TNM, tumor node metastasis.

https://doi.org/10.1371/journal.pone.0250295.t001
As an inflammatory parameter reflecting the immune responses and nutritional condition of patients, CAR was extensively explored as a prognostic marker in GC. The results regarding the association between CAR and survival outcomes were inconsistent according to previous studies.
studies. In the present meta-analysis, we synthetized data of 8 studies with 3,216 patients and found that high CAR was significantly associated with poor OS and CSS. In addition, the prognostic value of CAR was persistent in different subgroups of country, treatment, and cut-off value. We also identified the positive correlation between CAR and male sex, advanced tumor stage, and larger tumor size. Our meta-analysis demonstrated that CAR was an effective and reliable prognostic factor and a risk factor of tumor progression for patients with GC.

Recent evidence has shown the relationship between chronic inflammation and cancer in past decades [32, 33]. CRP is an acute phase protein and the production of CRP is independently mediated by interleukin 6 (IL-6) in liver. Recent studies have revealed that CRP can produce inflammatory cytokines and chemokines to facilitate cancer progression [34]. Moreover, albumin can reflect the nutrition status of host and decreased serum albumin levels are indicators of chronic diseases and malnutrition in cancer patients [35]. Therefore, CAR is a promising inflammation-based prognostic parameter because it combines CRP and albumin and is more stable than either one individually. CAR is initially shown as an independent

### Table 2. The subgroup analyses for the association between CAR and OS and CSS in gastric cancer.

| Subgroups       | No. of studies | No. of patients | Fixed-effects model | Random-effects model | Heterogeneity |
|-----------------|----------------|-----------------|---------------------|----------------------|---------------|
|                 |                |                 | HR (95%CI) p        | HR (95%CI) p         | I²(%) Ph      |
| OS              | Total          | 6               | 2,127               | 1.59(1.36–1.85) <0.001 | 1.59(1.36–1.85) <0.001 | 0.628         |
| Country         | China          | 3               | 1,050               | 1.51(1.26–1.80) <0.001 | 1.51(1.26–1.80) <0.001 | 0.414         |
|                 | Japan          | 3               | 1,077               | 1.86(1.36–2.55) <0.001 | 1.86(1.36–2.55) <0.001 | 0.811         |
| Treatment       | Surgery        | 4               | 1,532               | 1.74(1.39–2.17) <0.001 | 1.74(1.39–2.17) <0.001 | 0.856         |
|                 | Mixed          | 1               | 337                 | 1.78(1.20–2.65)      | 0.004         | -             |
|                 | Chemotherapy   | 1               | 258                 | 1.33(1.03–1.73) 0.030 | 1.33(1.03–1.73) 0.030 | -             |
| Cut-off value   | <0.2           | 3               | 1,077               | 1.86(1.36–2.55) <0.001 | 1.86(1.36–2.55) <0.001 | 0.811         |
|                 | ≥0.2           | 3               | 1,050               | 1.51(1.26–1.80) <0.001 | 1.51(1.26–1.80) <0.001 | 0.414         |
| TNM stage       | I-III          | 2               | 839                 | 1.73(1.31–2.28) <0.001 | 1.73(1.31–2.28) <0.001 | 0.386         |
|                 | IV             | 1               | 258                 | 1.33(1.03–1.73) 0.030 | 1.33(1.03–1.73) 0.030 | -             |
|                 | I-IV           | 2               | 790                 | 1.79(1.30–2.45) <0.001 | 1.79(1.30–2.45) <0.001 | 0.977         |
|                 | II             | 1               | 240                 | 1.71(1.02–2.87) 0.043 | 1.71(1.02–2.87) 0.043 | -             |
| CSS             | Total          | 3               | 1,473               | 1.65(1.21–2.25) 0.002 | 1.65(1.21–2.25) 0.002 | 0.919         |
| Country         | China          | 2               | 1,089               | 1.58(1.09–2.29) 0.015 | 1.58(1.09–2.29) 0.015 | 0.923         |
|                 | Japan          | 1               | 384                 | 1.82(1.03–3.22) 0.040 | 1.82(1.03–3.22) 0.040 | -             |
| Treatment       | Surgery        | 2               | 785                 | 1.76(1.05–2.95) 0.033 | 1.76(1.05–2.95) 0.033 | 0.775         |
|                 | Mixed          | 1               | 688                 | 1.59(1.08–2.35) 0.019 | 1.59(1.08–2.35) 0.019 | -             |
| Cut-off value   | <0.2           | 2               | 785                 | 1.76(1.05–2.95) 0.033 | 1.76(1.05–2.95) 0.033 | 0.775         |
|                 | ≥0.2           | 1               | 688                 | 1.59(1.08–2.35) 0.019 | 1.59(1.08–2.35) 0.019 | -             |
| TNM stage       | I-III          | 2               | 785                 | 1.76(1.05–2.95) 0.033 | 1.76(1.05–2.95) 0.033 | 0.775         |
|                 | II-III         | 1               | 688                 | 1.59(1.08–2.35) 0.019 | 1.59(1.08–2.35) 0.019 | -             |

https://doi.org/10.1371/journal.pone.0250295.t002
risk factor for mortality in septic patients [36]. Further studies reported the prognostic significance of CAR in various cancers including hepatocellular carcinoma (HCC) [17], renal cell carcinoma [18], anal carcinoma [37], and pancreatic cancer [38]. Those studies may suggest that CAR is a potential prognostic biomarker in solid tumors.

Previous meta-analyses have explored the prognostic value of CAR in a variety of cancers [15]. A meta-analysis based on 23 studies suggests that elevated level of serum CAR predicts

Fig 3. Forest plot of CAR in predicting CSS of patients with GC. (A) The whole patients group; (B) The subgroup analysis by country; (C) The subgroup analysis by treatment; (D) The subgroup analysis by cut-off value; and (E) The subgroup analysis by TNM stage.

https://doi.org/10.1371/journal.pone.0250295.g003
worse survival and unfavorable clinical characteristics in cancer patients [15]. Another meta-analysis on esophageal cancer (EC) also indicates that high pretreatment CAR is an adverse prognostic factor for EC patients, based on data of 8 studies with 2255 patients [39]. A recent meta-analysis comprising 9 studies also demonstrates that elevated pretreatment CAR is associated with poor OS and disease-free survival (DFS)/relapse-free survival (RFS) in colorectal cancer (CRC). In addition, high CAR is also correlated with several clinical features in patients with CRC [20]. In the present meta-analysis, we showed the prognostic impact of CAR and its
potential application as a risk factor in GC. Our results were in accordance with findings of previous meta-analyses of other cancer types [15, 20, 39]. In combination with other studies, we propose that CAR could be a novel and promising prognostic factor in cancer patients, especially gastrointestinal tumors including EC [39], GC, CRC [20], pancreatic cancer, and HCC [40].

We noticed that a meta-analysis on the prognostic value of CAR in GC was published very recently [41]. The work conducted by Yang and colleagues was elegant and they included 8 observational studies with 3102 patients in meta-analysis and reported that a high pretreatment CAR was significantly associated with poor survival for patients with GC [41]. When our meta-analysis was prepared, Yang’s work was not published, and our study was the first meta-analysis exploring the prognostic value of CAR in GC at that time. We applauded for Yang’s study; and those findings are important. However, our meta-analysis was different and provided additional information, compared with Yang’s work [41]. The novelty and strengths of our meta-analysis are highlighted in the following aspects. First, we provided additional and important findings. In our meta-analysis, we analyzed the correlation between CAR and clinicopathological features in GC. We identified the positive correlation between CAR and male sex, advanced tumor stage, and larger tumor size in GC. These findings suggest that a high CAR is predictive of tumor progression, which could aid in the managements of those high-risk patients. In Yang’s study [41], those analyses were not reported. Second, the included studies in our meta-analysis and in Yang’s work were different and the eligible studies in our meta-analysis were strictly selected by uniform inclusion and exclusion criteria, which guaranteed the credibility of the results. For example, we noticed that a study focusing on patients with adenocarcinoma of the esophagogastric junction (AEG) and upper gastric cancer (UGC) [42] was included in Yang’s meta-analysis. However, we excluded this study [42] after full-text examination because this study focused on patients with AEG and UGC, other than GC.

The cut-off value is important to identify patients with high or low CAR, therefore, the identifying of cut-off values could influence the subgroup of patients. Notably, the cut-off values are different in included studies for OS and CSS analysis. The investigators used various methods to determine the optimal cut-off value of CAR, including operating characteristics (ROC) curve and median value. In the subgroup analysis of the meta-analysis, both CAR<0.2 and CAR≥0.2 showed significant prognostic efficiency. We suggest that a uniform optimal cut-off value of CAR should be applied for GC in future researches.

Several limitations still should be acknowledged in the present meta-analysis. First, most of the included studies (7 out of 8) are retrospective cohort studies, which may increase the risk of selection bias. Second, the sample size was relatively small. Only 6 studies and 3 studies are included for the analysis of OS and CSS, the number of included studies and subjects was limited. Third, the cut-off values to identify high CAR levels were different in included studies.

### Table 3. Association between high levels of CAR and clinicopathological characteristics of patients with GC.

| Clinicopathological parameters | No. of studies | No. of patients | OR (95%CI) | p  | Heterogeneity | Effects model |
|--------------------------------|----------------|-----------------|------------|----|---------------|---------------|
| Sex (male vs female)           | 3              | 850             | 1.80(1.31–2.47) | <0.001 | 0 | 0.646 | Fixed |
| Age (≥median vs < median)      | 3              | 850             | 1.44(0.89–2.33) | 0.141 | 61.4 | 0.075 | Random |
| Tumor location (proximal vs remote and other) | 3              | 850             | 0.86(0.40–1.81) | 0.682 | 82.7 | 0.003 | Random |
| Platelets counts (≥median vs < median) | 2              | 513             | 2.40(0.67–8.56) | 0.179 | 75.2 | 0.045 | Random |
| TNM stage (III-IV vs I-II)     | 2              | 592             | 2.14(1.48–3.09) | <0.001 | 36.3 | 0.210 | Fixed |
| Tumor size (cm) (≥3 vs <3)     | 2              | 592             | 2.69(1.84–3.93) | <0.001 | 24.7 | 0.249 | Fixed |

https://doi.org/10.1371/journal.pone.0250295.t003
These diverse thresholds could lead to inconsistent recruitment of patients and cause heterogeneity among studies. Fourth, the sample size for the correlation of CAR and clinicopathological factors were relatively small. Only 3 studies with 850 cases were included, which may lead to selection bias in this meta-analysis.

Fig 5. Begg’s test for publication bias examination. (A) OS: $p = 0.133$, and (B) CSS: $p = 1$. 
https://doi.org/10.1371/journal.pone.0250295.g005
Conclusions
In summary, elevated pretreatment CAR is a prognostic marker of poor OS and CSS in patients with GC. Furthermore, high CAR levels are associated with clinicopathological features reflecting tumor progression. Thus, CAR has the potential to be applied as a useful marker for prognostication and identification of high-risk patients with GC. Considering several limitations to this meta-analysis, more large-scale clinical trials are still needed to confirm our results.

Supporting information
S1 Checklist. PRISMA checklist.
(DOC)

S1 Table. The details of the NOS scale for included studies in this meta-analysis.
(DOCX)

Author Contributions
Conceptualization: Junhua Yu, Huiling Liu, Yujun Zhao, Jun Qian.
Data curation: Huiling Liu, Xueyun Zeng, Yujun Zhao, Dejun Jiang, Hang Lu.
Formal analysis: Huiling Liu, Yujun Zhao, Dejun Jiang, Jun Qian.
Funding acquisition: Junhua Yu, Xueyun Zeng, Jun Qian.
Investigation: Junhua Yu, Yujun Zhao, Dejun Jiang, Hang Lu.
Methodology: Xueyun Zeng, Dejun Jiang.
Project administration: Hang Lu.
Resources: Junhua Yu, Huiling Liu, Xueyun Zeng, Hang Lu, Jun Qian.
Software: Huiling Liu.
Supervision: Yujun Zhao, Jun Qian.
Validation: Huiling Liu, Xueyun Zeng.
Visualization: Junhua Yu, Yujun Zhao, Hang Lu.
Writing – original draft: Junhua Yu, Xueyun Zeng, Dejun Jiang, Hang Lu.
Writing – review & editing: Yujun Zhao, Jun Qian.

References
1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016; 388(10060):2654–64. Epub 2016/05/10. https://doi.org/10.1016/S0140-6736(16)30354-3 PMID: 27156933.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6):394–424. Epub 2018/09/13. https://doi.org/10.3322/caac.21492 PubMed PMID: WOS:000498558800003. PMID: 31386635
3. Lyons K, Le LC, Pham YTH, Borron C, Park JY, Tran CTD, et al. Gastric cancer: epidemiology, biology, and prevention: a mini review. European Journal of Cancer Prevention. 2019; 28(5):397–412. https://doi.org/10.1097/CEJ.0000000000000480 PubMed PMID: WOS:000498558800003. PMID: 31386635
4. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Medicine. 2018; 7(1):123–33. https://doi.org/10.1002/cam4.1274 PubMed PMID: WOS:000425822300013. PMID: 29239137
5. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastroctomy for Stage IV Gastric Cancer: A Systematic Review and Meta-analysis. Anticancer Research. 2014; 34(5):2079–85. PubMed PMID: WOS:000355459000003. PMID: 24778009

6. Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2020; 23(4):565–78. https://doi.org/10.1007/s10120-020-01090-4 PubMed PMID: WOS:000536069000001. PMID: 32648420

7. Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine. 2020; 9(6). https://doi.org/10.3390/jcm9061894 PubMed PMID: WOS:000552493700001. PMID: 32560392

8. Zhou C, Zhong X, Song YX, Shi JX, Wu ZH, Guo ZX, et al. Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence. Frontiers in Oncology. 2019; 9. https://doi.org/10.3389/fonc.2019.00009 PubMed PMID: WOS:000502743100001. PMID: 30723704

9. Diakos CI, Charles KA, McMillian DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncology. 2014; 15(11):E493–E503. https://doi.org/10.1016/S1470-2045(14)70263-3 PubMed PMID: WOS:000343096800030. PMID: 25281468

10. Yang Y, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: A meta-analysis. Esoj. 2016; 42(8):1176–82. https://doi.org/10.1016/j.esoj.2016.05.029 PubMed PMID: WOS:000383005000011. PMID: 27293109

11. Li J, Xu R, Hu DM, Zhang Y, Gong TP, Wu XL. Prognostic Nutritional Index Predicts Outcomes of Patients after Gastrectomy for Cancer: A Systematic Review and Meta-Analysis of Nonrandomized Studies. Nutr Cancer. 2019; 71(4):557–58. Epub 2019/02/22. https://doi.org/10.1080/01635581.2019.1577986 PMID: 30793968.

12. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Critical Reviews in Clinical Laboratory Sciences. 2011; 48(4):155–70. https://doi.org/10.3109/10408363.2011.599831 PubMed PMID: WOS:000296283100001. PMID: 22035340

13. Li W, Luo X, Liu Z, Chen Y, Li Z. Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis. Plos one. 2018; 13(4):e0195769-e. https://doi.org/10.1371/journal.pone.0195769 PMID: 29668751.

14. Fang Y, Xu C, Wu P, Zhang L-H, Li D-W, Sun J-H, et al. Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma: A meta-analysis and literature review. Medicine. 2017; 96(45):e9463-e. https://doi.org/10.1097/MD.0000000000004643 PMID: 29137033.

15. Wu J, Tan W, Chen L, Huang Z, Mai S. Clinicopathologic and prognostic significance of C-reactive protein/albumin ratio in patients with solid tumors: an updated systemic review and meta-analysis. Oncotarget. 2018; 9(17):13934–47. Epub 2018/03/24. https://doi.org/10.18632/oncotarget.24172 PMID: 29568406; PubMed Central PMCID: PMC5862627.

16. Miyamoto T, Fujitani M, Fukuyama H, Hatanaka S, Koizumi Y, Kawabata A. The C-Reactive Protein/Albumin Ratio Is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients. Journal of Palliative Medicine. 2019; 22(5):532–7. https://doi.org/10.1089/jpm.2018.0404 PubMed PMID: WOS:000467304800012. PMID: 30570426

17. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology. 2015; 22(3):803–10. https://doi.org/10.1245/s10434-014-4048-0 PubMed PMID: WOS:000350531000018. PMID: 25190127

18. Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, et al. C-reactive protein/albumin ratio as a prognostic factor in renal cell carcinoma—A data from multi-institutional study in Japan. Urologic Oncology-Seminars and Original Investigations. 2019; 37(11). https://doi.org/10.1016/j.urolonc.2019.04.002 PubMed PMID: WOS:000492676200010. PMID: 31053528

19. Wang Y, Hu X, Huang Y, Xu WY, Wu YM, Li PF, et al. Prognostic value of the C-reactive protein to albumin ratio in esophageal cancer: A systematic review and meta-analysis. The Kaohsiung journal of medical sciences. 2019. Epub 2019/09/13. https://doi.org/10.1002/kjm2.12129 PMID: 31512813.

20. Zhou QP, Li XJ. C- Reactive Protein to Albumin Ratio in Colorectal Cancer: A Meta-Analysis of Prognostic Value. Dose-response: a publication of International Hormesis Society. 2019; 17(4):1559325819889814. Epub 2019/12/05. https://doi.org/10.1177/1559325819889814 PMID: 31798355; PubMed Central PMCID: PMC6868585.

21. Sun F, Ge X, Liu Z, Du S, Ai S, Guan W. Postoperative C-reactive protein/albumin ratio as a novel predictor for short-term complications following gastrectomy of gastric cancer. World J Surg Oncol. 2017;
22. Liu XC, Sun XW, Liu JJ, Kong PF, Chen SX, Zhan YQ, et al. Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Translational Oncology. 2015; 8(4):339–45. https://doi.org/10.1016/j.tranon.2015.06.006 PubMed PMID: WOS:000362076400013. PMID: 26310380

23. Ni XF, Wu J, Ji M, Shao YJ, Zhou WJ, Jiang JT, et al. Prognostic value of C-reactive protein/albumin ratio in patients receiving first-line palliative chemotherapy with unresectable stage IV gastric cancer. International Journal of Clinical and Experimental Pathology. 2016; 9(12):12785–96. PubMed PMID: WOS:000390462000067.

24. Toiyama Y, Shimura T, Yasuda H, Fujikawa H, Okita Y, Kobayashi M, et al. Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with Gastric Cancer. Anticancer Res. 2016; 36(12):6491–6. Epub 2016/12/07. https://doi.org/10.21873/anticancer.11248 PMID: 27919972.

25. Mao M, Wei X, Sheng H, Chi P, Liu Y, Huang X, et al. C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. Oncol Lett. 2017; 14(6):7417–24. Epub 2018/01/19. https://doi.org/10.3892/ol.2017.7179 PMID: 29344182; PubMed Central PMCID: PMC5755531.

26. Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, et al. Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin and Neutrophil-Lymphocyte Ratio in Gastric Cancer Patients. World journal of surgery. 2018; 42(6):1819–25. Epub 2017/12/23. https://doi.org/10.1007/s00268-017-4400-1 PMID: 29270856.

27. Toyokawa T, Muguruma K, Tamura T, Sakurai K, Amano R, Kubo N, et al. Comparison of the prognostic impact and combination of preoperative inflammation-based and/or nutritional markers in patients with stage II gastric cancer. Oncotarget. 2018; 9(50):29351–64. Epub 2018/07/24. https://doi.org/10.18632/oncotarget.25486 PMID: 30034622; PubMed Central PMCID: PMC6047670.

28. Liu XC, Wu ZM, Lin EZ, Li W, Chen YB, Sun XW, et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clinical Nutrition. 2019; 38(4):1853–60. https://doi.org/10.1016/j.clnu.2018.07.015 PubMed PMID: WOS:000473381200046. PMID: 30075998

29. Lu J, Xu BB, Zheng ZF, Xie JW, Wang JB, Lin JX, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2019; 22(3):536–45. Epub 2018/11/01. https://doi.org/10.1007/s10120-018-0892-0 PMID: 30377862.

30. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of Clinical Epidemiology. 2009; 62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005 PubMed PMID: WOS:000270250500003. PMID: 19631508

31. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology. 2010; 25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z PubMed PMID: WOS:000282102200001. PMID: 20652370

32. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321–30. https://doi.org/10.1038/nature21349 PubMed PMID: WOS:000396128000030. PMID: 28102259

33. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010; 140(6):883–99. https://doi.org/10.1016/j.cell.2010.01.025 PubMed PMID: WOS:000275746600012. PMID: 20303878

34. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. International Journal of Breast Cancer. 2015. https://doi.org/10.1155/2015/145647 PubMed PMID: WOS:0003728521500046. PMCID: 46693355

35. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goequipert R, Brom-Valladares R, Carrillo JF, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Annals of Surgical Oncology. 2007; 14(2):381–9. https://doi.org/10.1245/s10434-006-9093-x PubMed PMID: WOS:000243765500016. PMID: 17160496

36. Ranzani OT, Zampieri FG, Forte DN, Azevedo LCP, Park M. C-Reactive Protein/Albumin Ratio Predicts 90-Day Mortality of Septic Patients. Plos One. 2013; 8(3). https://doi.org/10.1371/journal.pone.0059321 PubMed PMID: WOS:000316252500080. PMID: 23555017

37. Martín D, Rodel F, Ballemapas P, Winkelmann R, Fokas E, Rodel C. C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. Frontiers in Oncology. 2019;9. https://doi.org/10.3389/fonc.2019.00009 PubMed PMID: WOS:000498891180001. PMID: 30723704
38. Liu ZQ, Jin KZ, Guo M, Long J, Liu L, Liu C, et al. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Annals of Surgical Oncology. 2017; 24(2):561–8. https://doi.org/10.1245/s10434-016-5579-3 PubMed PMID: WOS:000391926600037. PMID: 27650825

39. Liu Z, Shi H, Chen L. Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis. BMC Cancer. 2019; 19(1):1161. Epub 2019/12/01. https://doi.org/10.1186/s12885-019-6373-y PMID: 31783812.

40. Fan Y, Gu X, Gao Z. Prognostic value of C-reactive protein to albumin ratio in patients with hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol. 2019. Epub 2019/08/25. https://doi.org/10.1016/j.clinre.2019.07.014 PMID: 31444039.

41. Yang X, Song X, Zhang L, Wu C. Prognostic role of the pretreatment C-reactive protein/albumin ratio in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(10):e19362. Epub 2020/03/10. https://doi.org/10.1097/MD.00000000000019362 PMID: 32150079.

42. Kudou K, Saeki H, Nakashima Y, Kamori T, Kawazoe T, Haruta Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastrectomy and upper gastric cancer. Journal of Gastroenterology and Hepatology. 2019; 34(2):355–63. https://doi.org/10.1111/jgh.14442 PubMed PMID: WOS:000459628400011. PMID: 30119141